Skip to main
SMMT
SMMT logo

Summit Therapeutics (SMMT) Stock Forecast & Price Target

Summit Therapeutics (SMMT) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 29%
Hold 12%
Sell 6%
Strong Sell 0%

Bulls say

Summit Therapeutics Inc is poised for significant growth, driven by the favorable clinical performance of its product candidates, particularly ridinilazole for Clostridiodes difficile infection. The encouraging results from the HARMONi trial, with 65% of patients already showing a progression-free survival (PFS) benefit, enhance confidence in successful outcomes for upcoming data readouts in 2025. Furthermore, predictions of substantial peak annual sales for its oncology treatments reveal the potential for market competitiveness, positioning Summit favorably in the biopharmaceutical landscape.

Bears say

Summit Therapeutics's outlook remains negative primarily due to significant regulatory and clinical risks associated with its product candidates. The potential for marginal clinical efficacy or the emergence of new safety signals in ongoing trials lowers the probability of success for its treatments, which may lead to price declines despite meeting investor expectations. Additionally, the lack of differentiated clinical data and concerns about competition, coupled with a projected net loss per share and potential dilution risks, further exacerbate the concerns surrounding the company’s financial stability.

Summit Therapeutics (SMMT) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 29% recommend Buy, 12% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Summit Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Summit Therapeutics (SMMT) Forecast

Analysts have given Summit Therapeutics (SMMT) a Buy based on their latest research and market trends.

According to 17 analysts, Summit Therapeutics (SMMT) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Summit Therapeutics (SMMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.